{
    "Rank": 380,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03235765",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "SNUBH-17-01"
                },
                "Organization": {
                    "OrgFullName": "Seoul National University Hospital",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Cancer Panel From Blood of Lung Cancer Patients",
                "OfficialTitle": "Clinical Validity of Oncogenic Driver Genes Detected From Circulating Tumor DNA in Blood of Lung Cancer Patients",
                "Acronym": "CAPABLE"
            },
            "StatusModule": {
                "StatusVerifiedDate": "January 2019",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Active, not recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 10, 2017",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "March 10, 2019",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "March 10, 2020",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "July 28, 2017",
                "StudyFirstSubmitQCDate": "July 28, 2017",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "August 1, 2017",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "January 18, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "January 22, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Jong-Seok Lee",
                    "ResponsiblePartyInvestigatorTitle": "Professor",
                    "ResponsiblePartyInvestigatorAffiliation": "Seoul National University Bundang Hospital"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Seoul National University Hospital",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "MACROGEN",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by NGS technique).",
                "DetailedDescription": "This study is comprised of two cohorts as below:\n\nCohort A: inoperable, untreated, non-small cell lung cancer patients\n\nCohort B: non-small cell lung cancer patients who are in the treatment with targeted agents including immune checkpoint inhibitors"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Non Small Cell Lung Cancer Metastatic",
                        "Non Small Cell Lung Cancer Recurrent"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "NSCLC",
                        "Cancer panel",
                        "NGS",
                        "Actionable mutation",
                        "Immune checkpoint inhibitor"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "PatientRegistry": "Yes",
                "TargetDuration": "3 Years",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Cohort"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "BioSpec": {
                    "BioSpecRetention": "Samples With DNA",
                    "BioSpecDescription": "Cancer panel analysis will be done with patients tumro tissue and ctDNA"
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "200",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Cohort A",
                            "ArmGroupDescription": "Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Cohort B",
                            "ArmGroupDescription": "Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Diagnostic Test",
                            "InterventionName": "MACROGEN Pan Cancer Panel (Tier 2)",
                            "InterventionDescription": "This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Cohort A",
                                    "Cohort B"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Concordance rate",
                            "PrimaryOutcomeDescription": "Concordance rate of genomic change between tumor tissue (FFPE) and ctDNA",
                            "PrimaryOutcomeTimeFrame": "an average of one year"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Overall survival",
                            "SecondaryOutcomeDescription": "To evaluate prognostic role of ctDNA concentration in NSCLC",
                            "SecondaryOutcomeTimeFrame": "an average of one year"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Frequency of actionable genomic change",
                            "SecondaryOutcomeDescription": "To determine the frequency of actionable oncogenic genes in NSCLC",
                            "SecondaryOutcomeTimeFrame": "an average of one year"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall survival by treatment",
                            "SecondaryOutcomeDescription": "To evaluate the survival of patients treated with genotype-directed therapy in daily practice",
                            "SecondaryOutcomeTimeFrame": "an average of one year"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nProvision of informed consent prior to any study specific procedures, sampling, and analyses\nPathologically confirmed non-small cell lung cancer\nMale or female, aged at least 20 years\n\nMatches one of two criteria :\n\nCohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy\nCohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.\n\nExclusion Criteria:\n\nAny concurrent and/or other active malignancy that has required treatment within 3 years\nPatients with mixed small cell histology\nLife expectancy less than 3 months\nInsufficient tissue for NGS test",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "20 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Inoperable non-small cell lung cancer with two cohorts as below:\n\nCohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy\nCohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Seoul National University Bundang Hospital",
                            "LocationCity": "Seongnam",
                            "LocationZip": "463-707",
                            "LocationCountry": "Korea, Republic of"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "Undecided"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000002289",
                            "ConditionMeshTerm": "Carcinoma, Non-Small-Cell Lung"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000002283",
                            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
                        },
                        {
                            "ConditionAncestorId": "D000001984",
                            "ConditionAncestorTerm": "Bronchial Neoplasms"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5236",
                            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
                            "ConditionBrowseLeafAsFound": "Non-Small Cell Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5230",
                            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4950",
                            "ConditionBrowseLeafName": "Bronchial Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M2343",
                            "InterventionBrowseLeafName": "Immune Checkpoint Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}